Hemodialysis: Yesterday, today and tomorrow

Minerva Urologica e Nefrologica

Volumn 62, Issue 1, 2010, Pages 1-12

  Cavalli, A ^a   Del Vecchio, L ^a   Manzoni, C ^a   Locatelli, F ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Renal dialysis; Renal dialysis, adverse effects; Renal dialysis, history

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BICARBONATE; BORTEZOMIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; RENIN INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; ALBUMIN BLOOD LEVEL; BLOOD PRESSURE REGULATION; BLOOD VOLUME; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; DIALYSATE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART FAILURE; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; HYPOVOLEMIA; INCIDENCE; INTOXICATION; MEMBRANE PERMEABILITY; MULTIPLE MYELOMA; QUALITY OF LIFE; REVIEW; SODIUM BALANCE; VASCULAR ACCESS; VOMITING;

HEART FAILURE; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; MULTIPLE MYELOMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953496194     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Kolff WJ, Berk HTHJ, Welle M, Van der Ley AJ, Van Dijk EC, Van Noordwijc J. The artificial kidney: A dialyser with a great area. Acta Med Scand 1944;177:121-34.
2. Quinton W, Dillard D, Scribner BH. Cannulation of blood vessels for prolonged hemodialysis. Trans Am Soc Artif Intern Organs 1960;6:104-13.
3. Brescia MJ, Cimino JE, Appel K, Hurwich BJ, Scribner BH. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N Engl J Med 1966;275:1089-92.
4. Friedman EA. Kolff's contributions provoked the birth of ethics in nephrology. Artif Organs 1998;22:940-4.
5. Jungers P, Chauveau P, Descamps-Latscha B, Labrauni M, Giraud E, Man NK et al. Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study. Nephrol Dial Transplant 1996;11:1542-6.
6. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007;56:161-5.
7. Eggers PW, Connerton R, McMullan M. The Medicare experience with end-stage renal disease: Trends in incidence, prevalence, and survival. Health Care Fin Rev 1984;5:69-88.
8. Eggers PW. Clinical aspects for which treatment with the artificial kidney is to be considered. In: Rettig RA, Levinsky, NG, editors. Kidney Failure and the Federal Government. Washington, DC: National Academy Press; 1991. p. 82.
9. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005;45:S1-S280.
10. United States Renal Data System 1998 Annual Data Report. Am J Kidney Dis 1998;32:S38-S41.
11. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A et al. United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis 2009;53:S1-S374.
12. Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007;146:177-83.
13. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28:526-34
14. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996;50: 550-56
15. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, et al. Effect of the dialysis membrane on mortality of chronic haemodialysis patients. Kidney Int 1996; 50:566-70
16. Koda Y, Nishi S, Miyazaki S, Haginoscita S, Sakurabayashi T, Suzuki M, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997;52:1096-101.
17. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G et al. and the Italian Cooperative Dialysis Study Group: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996;50:1293-302.
18. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Green T, Kusek JW et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-9.
19. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int 1999;55:286-93.
20. Locatelli F, Cavalli A, Tucci B. The growing problem of intradialytic hypertension. Nat Rev Nephrol 2010;6: 41-8.
21. Gotch FA, Lam MA, Prowitt M, Keen M. Preliminary clinical results with sodium-volume modelling of hemodialysis therapy. Proc Clin Dial Transplant Forum 1980;10:12-7.
22. Di Filippo S, Corti M, Andrulli S, Manzoni C, Locatelli F. Determining the adequacy of sodium balance in hemodialysis uding a kinetic model. Blood Purif 1996;14: 431-6.
23. Locatelli F, Di Filippo S, Manzoni C. Relevance of the conductivity kinetic model in the control of sodium pool. Kidney Int 2000;58:S89-S95. (Pubitemid 30612807)
24. Bogaard HJ, de Vries JPPM, de Vries PMJM. Assessment of refill and hypovolaemia by continuous surveillance of blood volume and extracellular fluid volume. Nephrol Dial Transplant 1994;9:1283-7.
25. Barth C, Boer W, Garzoni D, Kuenzi T, Ries W, Schaefer R et al. Characteristics of hypotension-prone haemodialysis patients: is there a critical relative blood volume? Nephrol Dial Transplant 2003;18:1353-60.
26. Donauer J, Kolblin D, Bek M, Krause A, Böhler J. Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects. Am J Kidney Dis 2000;36:115-23.
27. Santoro A, Mancini E, Basile C, Amoroso L, Di Giulio S, Usberti M et al. Blood volume controlled hemodialysis in hypotension-prone patients: a randomized, multicenter controlled trial. Kidney Int 2002;62:1034-45.
28. Franssen CF, Dasselaar JJ, Sytsma P, Burgerhof JG, de Jong PE, Huisman RM. Automatic feedback control of relative blood volume changes during hemodialysis improves blood pressure stability during and after dialysis. Hemodial Int 2005;9:383-92.
29. Gabrielli D, Kristal B, Katzarski K, Youssef M, Hachache T, Lopot F et al. Improved intradialytic stability during haemodialysis with blood volume-controlled ultrafiltration. J Nephrol 2009;22:232-40.
30. Andrulli S, Colzani S, Mascia F, Lucchi L, Stipo L, Bigi MC et al. The role of blood volume reduction in the genesis of intradialytic hypotension. Am J Kidney Dis 2002;40:1244-54.
31. Locatelli F, Cavalli A, Tucci B, Viganò S, Di Filippo S. Can chronic volume overload be recognized and prevented in hemodialysis patients? Newer methods to assess volume status. Semin Dial 2009;22:492-4.
32. Inrig JK, Patel UD, Toto RD, Szczech LA. Association of blood pressure increases during hemodialysis with 2?year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 study. Am J Kidney Dis 2009;54:881-90.
33. Dasselaar JJ, Huisman RM, De Jong PE, Burgerhof JG, Franssen CF. Effects of relative blood-volume controlled hemodialysis on blood pressure and volume status in hypertensive patients. ASAIO J 2007;53:357-64.
34. Locatelli F, Manzoni C, Cavalli A, Di Filippo S. Can convective therapies improve dialisi outcomes? Curr Opin Nephrol Hypertens 2009;18:476-80.
35. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Green T, Kusek JW, for the Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in the maintenance hemodialysis. N Engl J Med 2002;347:2010-9.
36. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003;14:3251-63.
37. Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK et al. Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO study. Am J Kidney Dis 2006;47:131-8.
38. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009;20:645-54.
39. Cheung AK, Greene T. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009;20:462-4.
40. Tattersall J, Canaud B, Heimburger O, Pedrini L, Schneditz D, Van Biesen W; European Renal Best Practice advisory Board. High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome study. Nephrol Dial Transplant 2009 [Epub ahead of print].
41. Leypoldt JK. Solute fluxes in different treatment modalities. Nephrol Dial Transplant 2000;15:S3-S9.
42. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006;69:2087-93.
43. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G et al. The Italian Cooperative Dialysis Study Group. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996;50:1293-02.
44. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. The Registro Lombardo Dialisi E Trapianto. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int 1999;55:286-93.
45. Schiffl H. Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis. Eur J Med Res 2007;12:26-33. (Pubitemid 46299313)
46. Van der Weerd NC, Penne EL, Van den Dorpel MA, Grooteman MPC, Nube MJ, Bots ML et al. Haemodiafiltration: promise for the future? Nephrol Dial Transplant 2008;23:438-43.
47. Canaud BJ. Changing paradigms of renal replacement therapy in chronic kidney disease patients: ultrapure dialysis fluid and high-efficiency hemodiafiltration for all? Kidney Int 2009;76:591-3.
48. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 2003;42:1020-35.
49. Williams AW, Chebrolu SB, Ing TS, Ting G, Blagg CR, Twardowski ZJ et al. Daily Hemodialysis Study Group: Early clinical 'quality of life, and biochemical changes of "daily hemodialysis" (6 dialysis per week). Am J Kidney Dis 2004;43:90-112.
50. Locatelli F, Buoncristiani U, Canaud B, Kohler H, Petitclerc T, Zucchelli P. Dialysis dose and frequency. Nephrol Dial Transplant 2006;20:285-96.
51. Blagg CR, Kjellstrand CM, Ting GO, Young BA. Comparison of survival between short-daily hemodialysis and conventional hemodialysis using the standardized mortality ratio. Hemodial Int 2006;10:371-4.
52. Kjellstrand CM, Buoncristiani U, Ting G, Traeger J, Piccoli GB, Sibai-Galland R et al. Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years. Nephrol Dial Transplant 2008;23:3283-9.
53. Johansen KL, Zhang R, Huang Y, Chen SC, Blagg CR, Goldfarb-Rumyantzev AS et al. Survival and hospitalization among patients using nocturnal and short daily compared to conventional hemodialysis: a USRDS study. Kidney Int 2009;76:984-90.
54. Punal J, Lema LV, Sanhez-Guisande D, Ruano-Ravina A. Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis: a systematic review. Nephrol Dial Transplant 2008;23:2634-46.
55. Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis 2003;42:S36-S41. (Pubitemid 36807681)
56. Lee CP, Zenios SA, Chertow GM. Cost-effectiveness of frequent in-center hemodialysis. J Am Soc Nephrol 2008;19:1792-7.
57. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barret BJ et al. Canadian Apheresis Group: plasma exchange when myeloma presents as acute renal failure: a randomised controlled trial. Ann Intern Med 2005;143:777-84.
58. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J et al. Removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18: 886-95.
59. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4:745-54.
60. Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A et al. European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy (EuLITE): A randomised control trial. Trials 2008;9:55.
61. Biggers JA, Remmers AR, Glassford DM, Lindley JD, Sarles HE, Fish JC. Bovine graft fistulas in patients with vascular access problems receiving hemodialysis. Surg Gynecol Obstet 1975;140:690-2.
62. Schwab SJ, Buller GL, McCann RL, Bollinger RR, Stickel DL. Prospective evaluation of a Dacron cuffed hemodialysis catheter for prolonged use. Am J Kidney Dis 1988;11:166-9.
63. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL. Vascular access results from the Dialysis Outcomes and Practice Pattern Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines. Am J Kidney Dis 2004;44:S22-S6.
64. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Vascular Access, 2000. Am J Kidney Dis 2001;37:S137-S81.
65. Lok CE. Fistula first initiative: advantages and pitfalls. Clin J Am Soc Nephrol 2007;2:1043-53.
66. Ethier J, Mendelssohn DC, Elder SJ, Hasegawa T, Akizawa T, Akiba T et al. Vascular access use and outcomes: an international perspective from the dialysis outcomes and practice patterns study. Nephrol Dial Transplant 2008;23:3219-26.
67. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48:S2-S90.
68. Davenport A, Gura V, Ronco C, Beizai M, Ezon C, Rambod E. A wearable haemodialysis device for patients with end-stage renal failure: a pilot study. Lancet 2007;370:2005-10.
69. Gura V, Ronco C, Davenport A. The wearable artificial kidney, why and how: from holy grail to reality. Semin Dial 2009;22:13-7.
70. Kolff WJ, Jacobsen S, Stephen RL, Rose D. Towards a wearable artificial kidney. Kidney Int Suppl 1976;S300-S4.
71. Shaldon S, Beau MC, Deschodt G, Lysaght MJ, Ramperez P, Mion C. Continuous ambulatory hemofiltration. Trans Am Soc Artif Intern Organs 1980;26:210-23.
72. Murisasco A, Reynier JP, Ragon A, Boobes Y, Baz M, Durand C et al. Continuous arterio-venous hemofiltration in a wearable device to treat end-stage renal disease. Trans Am Soc Artif Intern Organs 1986;32:567-71.
73. Eknoyan G. Artificial kidneys: progress and promise. Lancet 2007;370:1977-8.
74. Shaldon S, Lysaght MJ. A wearable hemofilter for continuous ambulatory ultrafiltration. Kidney Int 2008;74:537.
75. Shaldon S, Lysaght MJ. Wearable artificial kidney.... 2008. What's new? Nephrol Dial Transplant 2008;23:2716-7.
76. Shaldon S. A wearable haemodialysis device. Lancet 2008;371:1163.